This integrated model aligns with the evolving understanding of obesity as a chronic metabolic condition, not a matter of willpower or appearance
SM: Advisory boards: AstraZeneca, Boehringer Ingelheim, Intarcia Therapeutics, Novo Nordisk, Sanofi, Abbott Lab, Bayer, Amgen
10.1007/s00125-010-1874-x [DOI] [PMC free article] [PubMed] [Google Scholar] 8.Smith KJ et al (2013) Association of diabetes with anxiety: a systematic review and meta-analysis
Similar to the SGLT2 inhibitors [1, 4, 13], GLP-1RAs also mildly reduced systolic and diastolic blood pressure in the trials
(13) Preclinical studies have demonstrated that GLP-1 receptor agonists like exenatide can enhance bone mass in diabetic and insulin-resistant rat models by upregulating OPG expression and improving the OPG/RANKL ratio